Breast最新文献

{"title":"Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study","authors":"T. De La Motte Rouge ,&nbsp;J.-S. Frenel ,&nbsp;C. Cropet ,&nbsp;E. Borcoman ,&nbsp;A. Hervieu ,&nbsp;G. Emile ,&nbsp;P. Augereau ,&nbsp;E. Charafe ,&nbsp;F. Legrand ,&nbsp;E. Dassé ,&nbsp;A. Gonçalves","doi":"10.1016/j.breast.2025.104549","DOIUrl":"10.1016/j.breast.2025.104549","url":null,"abstract":"<div><h3>Purpose</h3><div>MOVIE assessed the enhancement of immunotherapy activity in advanced breast cancer (BC) tumors with metronomic chemotherapy associated to dual ICI combination.</div></div><div><h3>Methods</h3><div>MOVIE was a national, multicenter, open-label, phase I/II, non-randomized. It tested the antitumor activity and safety of metronomic vinorelbine associated with anti-PD-L1 durvalumab + anti-CTLA-4 tremelimumab using a Bayesian approach. Here, we report on the cohort of patients with advanced BC during MOVIE phase 2. Patients were aged≥18 years with histologically confirmed locally advanced or metastatic breast tumors, resistant to conventional therapies, presenting a measurable disease according to RECISTv1.1. They received vinorelbine 40 mg thrice a week, and durvalumab 1500 mg plus tremelimumab 75 mg at day 1 of 28-day cycles. The primary endpoint was clinical benefit rate (CBR). Secondary endpoints included safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</div></div><div><h3>Results</h3><div>Between 2018 and 2020, 30 BC patients, including 19 triple negative breast cancers were enrolled. Mean estimated CBR (95 % credible interval) using a non-informative prior was 15.6 % (5.5–29.8). ORR was 6.7 % (2 PR), median PFS 1.8 months (95 % confidence interval [CI]:1.8–1.8) and median OS 8.8 months (95 %CI:5.6–12.8). Fifteen patients (50.0 %) presented grade≥3 ICI-related adverse events (AEs), mostly fatigue (N = 3; 10.0 %). Grade≥3 vinorelbine-related AEs mostly included neutropenia (N = 5; 16.7 %), and fatigue (N = 3; 10.0 %). Four (13.3 %) patients discontinued their treatment due to treatment-related toxicity. There was no treatment-related death.</div></div><div><h3>Conclusion</h3><div>Metronomic vinorelbine and durvalumab plus tremelimumab showed limited antitumor activity in pretreated advanced BC. Alternative strategies are warranted to enhance the efficacy of ICI in those tumors.</div></div><div><h3>Trial registration</h3><div>This trial is registered with <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, identifier NCT03518606.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104549"},"PeriodicalIF":7.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing incidence of breast cancer in young women over time","authors":"Pascal Pujol ,&nbsp;Laurent Remontet ,&nbsp;Bénédicte Lapôtre-Ledoux ,&nbsp;Agnès Rogel ,&nbsp;Lionel Lafay ,&nbsp;Florence Molinié","doi":"10.1016/j.breast.2025.104555","DOIUrl":"10.1016/j.breast.2025.104555","url":null,"abstract":"<div><div>The incidence of early-onset breast cancer (EOBC) has recently been shown to be increasing over time in the US and the UK.</div><div>Using national cancer registries data including 229,352 BC cases, we show that the incidence rate of EOBC in France increased steadily from 1990 to 2023, rising from 16.1 (95 % CI: 14.7–17.8) to 26.3 (95 % CI: 20.7–33.3) and from 98.7 (95 % CI: 93.8–103.7) to 131.2 (95 % CI: 115.8–148.7) per 100,000 person-years in women aged 30 and 40 years, respectively.</div><div>This population-based study confirms that the incidence of EOBC is increasing over time in Western countries. Further research is needed to explain this trend, which may have implications for prevention and screening strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104555"},"PeriodicalIF":7.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China","authors":"Yamin Shu ,&nbsp;Ying Tang ,&nbsp;Yiling Ding ,&nbsp;Pingping Xu ,&nbsp;Qilin Zhang","doi":"10.1016/j.breast.2025.104550","DOIUrl":"10.1016/j.breast.2025.104550","url":null,"abstract":"<div><h3>Purpose</h3><div>Sacituzumab tirumotecan (sac-TMT), a trop-2-targeted antibody-drug conjugate, has demonstrated significant clinical benefit in the OptiTROP-Breast01 trial for patients with advanced or metastatic triple-negative breast cancer (TNBC). This study evaluated the cost-effectiveness of sac-TMT compared with chemotherapy from the perspective of the Chinese healthcare system.</div></div><div><h3>Methods</h3><div>A partitioned survival model incorporating multiple survival extrapolation approaches was developed to estimate long-term clinical and economic outcomes. Survival data were reconstructed from the OptiTROP-Breast01 trial, while cost and utility inputs were derived from publicly databases and literature. Outcomes included life-years, quality-adjusted life-years (QALYs), total costs, and key economic endpoints: incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), incremental net monetary benefit (INMB), and expected value of perfect information (EVPI). Sensitivity, scenario, and subgroup analyses were conducted to assess uncertainty.</div></div><div><h3>Results</h3><div>In the base-case analysis, sac-TMT yielded an additional 0.32 QALYs and 0.35 life-years compared with chemotherapy, with an incremental cost of $31815.17, resulting in an ICER of $98796.02 per QALY, exceeding the $40763.34 threshold in China. One-way sensitivity analysis identified the dose intensity, utility for PFS, patient weight, and price of sac-TMT as key drivers of ICER. Scenario analysis showed that reducing the drug price to 20 % of the current level would lower the ICER to $13319.46/QALY, with a 99.82 % probability of cost-effectiveness. EVPI was estimated at $33.69 per person.</div></div><div><h3>Conclusion</h3><div>While sac-TMT offers survival benefits in metastatic TNBC, it is unlikely to be cost-effective at current pricing. Substantial price reductions and optimized use may improve its economic value and support reimbursement.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104550"},"PeriodicalIF":7.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis","authors":"Gabriel Berlingieri Polho ,&nbsp;Yumi Ricucci Shinkado ,&nbsp;Leticia Kimie Murazawa ,&nbsp;Vinicius Vitor Oliveira ,&nbsp;Victor Rocha Pinheiro ,&nbsp;Diana del Cisne Pineda Labanda ,&nbsp;Romualdo Barroso-Sousa ,&nbsp;Luciana Rodrigues Carvalho Barros ,&nbsp;Laura Testa ,&nbsp;Renata Colombo Bonadio","doi":"10.1016/j.breast.2025.104553","DOIUrl":"10.1016/j.breast.2025.104553","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is associated with an increased risk of distant metastases. While pathological complete response (pCR) after neoadjuvant chemotherapy predicts favorable outcomes, data suggest it may not uniformly protect against central nervous system (CNS) relapse.</div><div>This study analyzed 774 TNBC patients to assess recurrence patterns. While CNS recurrences were numerically lower in pCR patients (5.0 % vs 8.8 %, p = 0.11), they represented a significantly higher proportion of all relapses in this group (50.0 % vs 20.2 %, p = 0.003). These results suggest that while pCR reduces overall recurrence risk, there is a distinct pattern of CNS-predominant failure.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104553"},"PeriodicalIF":7.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study","authors":"Leandro Jonata de Carvalho Oliveira ,&nbsp;Daniela Dornelles Rosa ,&nbsp;Artur Katz ,&nbsp;Daniele Assad-Suzuki ,&nbsp;Daniel Argolo ,&nbsp;Solange Moraes Sanches ,&nbsp;Laura Testa ,&nbsp;José Bines ,&nbsp;Rafael Aliosha Kaliks ,&nbsp;Debora de Melo Gagliato ,&nbsp;Romualdo Barroso-Sousa ,&nbsp;Tatiana Strava Corrêa ,&nbsp;Andrea Kazumi Shimada ,&nbsp;Carlos Henrique dos Anjos ,&nbsp;Rudinei Linck ,&nbsp;Thais Baccili Cury Megid ,&nbsp;Daniel Negrini Batista ,&nbsp;Daniel Musse Gomes ,&nbsp;Marcelle Goldner Cesca ,&nbsp;Débora Gaudêncio ,&nbsp;Max Senna Mano","doi":"10.1016/j.breast.2025.104554","DOIUrl":"10.1016/j.breast.2025.104554","url":null,"abstract":"<div><h3>Background</h3><div>In pivotal CDK4/6 inhibitor (CDK4/6i) adjuvant trials, most patients received chemotherapy (CT). However, the role of CDK4/6i in patients spared CT by a genomic signature remains unclear. We investigated the proportion of patients without genomic CT indication but eligible for adjuvant abemaciclib or ribociclib, and estimated their potential benefit from CDK4/6i.</div></div><div><h3>Methods</h3><div>This retrospective, real-world study included patients with T1–T3, N0–N1, HR+/HER2− early breast cancer (eBC) who underwent Oncotype DX (ODX) testing (2005–2024) at nine Brazilian institutions. Genomic CT indication followed TAILORx and RxPONDER; CDK4/6i eligibility followed MonarchE and NATALEE. Primary endpoints were 5-year invasive disease-free survival (iDFS) and distant disease-free survival (DDFS) among patients eligible for CDK4/6i, without genomic CT indication, treated with endocrine therapy (ET) alone.</div></div><div><h3>Results</h3><div>Among 922 patients, ODX showed low (&lt;11), intermediate (11–25), and high (&gt;25) genomic risk in 170 (18.4 %), 585 (63.5 %), and 167 (18.1 %), respectively. Overall, 24 (2.6 %) and 120 (13 %) were eligible for abemaciclib and ribociclib, respectively, had no CT indication, and received ET alone. In these patients (median follow-up: 57.8 and 66.4 months), 5-year iDFS and DDFS were 100 %.</div></div><div><h3>Conclusions and relevance</h3><div>HR+/HER2− eBC patients eligible for CDK4/6i but spared CT by ODX are a minority and have excellent outcomes with ET alone. This highlights the potential benefits of integrating genomic and clinical risk stratification to refine therapeutic decision-making regarding the need for CDK4/6i.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104554"},"PeriodicalIF":7.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A preoperative predictive model for margin status in breast-conserving surgery","authors":"Xinyu Liu ,&nbsp;Yan Liu ,&nbsp;Shichao Zhang ,&nbsp;Tao Ma ,&nbsp;Lei Liu ,&nbsp;Jin Zhang","doi":"10.1016/j.breast.2025.104548","DOIUrl":"10.1016/j.breast.2025.104548","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Positive margins after breast-conserving surgery (BCS) not only frequently necessitate re-excision but also represent the most significant risk factor for local recurrence. This study aimed to identify preoperative predictors of positive margins in BCS and establish a predictive model.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis was conducted on 2837 patients with primary breast cancer (BC) who underwent BCS at Tianjin Medical University Cancer Institute &amp; Hospital between June 2014 and June 2024. All patients underwent preoperative imaging evaluations, including ultrasonography (US), mammography (MG), and magnetic resonance imaging (MRI). Patients were randomly divided into a training cohort (n = 1,986, 70 %) and a validation cohort (n = 851, 30 %). A nomogram was developed in the training cohort using univariate and multivariate logistic regression to identify significant clinicopathological and imaging predictors. Discrimination was evaluated by calculating the C-index, while the Hosmer-Lemeshow goodness-of-fit test was applied to validate calibration performance.</div></div><div><h3>Results</h3><div>The positive margin rate in our cohort was 18.6 %. The predictive model incorporated seven variables: histological type; MRI parameters including maximum lesion size, fibroglandular tissue (FGT), background parenchymal enhancement (BPE), non-mass enhancement (NME), multifocality, and axillary lymph node metastasis (ALNM). C-indices were calculated of 0.782 (95 % CI: 0.757–0.807) and 0.761 (95 % CI: 0.719–0.803) for the modeling and the validation group, respectively. Hosmer-Lemeshow test:X-squared = 3.3163, df = 3, p-value = 0.3454.</div></div><div><h3>Conclusion</h3><div>We developed and validated a preoperative nomogram for predicting the risk of positive margins in BCS, integrating key clinicopathological and imaging parameters.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104548"},"PeriodicalIF":7.9,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial","authors":"Isabelle Demeestere ,&nbsp;Samuel M. Niman ,&nbsp;Ann H. Partridge ,&nbsp;Daniela S. Diego ,&nbsp;Roswitha Kammler ,&nbsp;Monica Ruggeri ,&nbsp;Marco Colleoni ,&nbsp;Chikako Shimizu ,&nbsp;Cristina Saura ,&nbsp;Karen A. Gelmon ,&nbsp;Anna B. Saetersdal ,&nbsp;Judith R. Kroep ,&nbsp;Audrey Mailliez ,&nbsp;Frederic Amant ,&nbsp;Manuel Ruız-Borrego ,&nbsp;Jeong Eon Lee ,&nbsp;Akemi Kataoka ,&nbsp;Janice M. Walshe ,&nbsp;Junko Takei ,&nbsp;Simona Borstnar ,&nbsp;Fedro A. Peccatori","doi":"10.1016/j.breast.2025.104547","DOIUrl":"10.1016/j.breast.2025.104547","url":null,"abstract":"<div><h3>Purpose</h3><div>The POSITIVE trial showed that premenopausal women with breast cancer (BC) can safely pause adjuvant endocrine treatment (ET) to attempt conception. 74 % of patients conceived spontaneously or through assisted reproductive technology (ART); Investigating hormonal factors that predict fertility was a key secondary endpoint.</div></div><div><h3>Methods</h3><div>Hormonal factors were assessed in non-pregnant women at months 3, 6, and 12 after ET interruption. The frequency of low ovarian reserve, defined as anti-Mullerian hormone (AMH) &lt; 0.5 ng/mL at month 3, and of premature ovarian insufficiency (POI), defined as follicle stimulating hormone (FSH) &gt; 25 IU/L at month 12, were primary measures. Secondary analyses to predict pregnancy included AMH, FSH, thyroid stimulating hormone (TSH), prolactin and ovulatory status (defined as progesterone &gt;3 ng/mL at month 6), considering covariates such as age, treatment, and ART use.</div></div><div><h3>Results</h3><div>Of 518 women enrolled in POSITIVE, 438 were eligible for low ovarian reserve analysis. Low ovarian reserve was observed in 209 women (47.7 %), more frequently among older women and those with prior chemotherapy, but not in relation to ET type or duration. Overall, low ovarian reserve was associated with reduced odds of pregnancy (OR:0.52; 95 % CI:0.31–0.87). Of 142 patients evaluated for POI, 16.7 % of those who received prior chemotherapy experienced POI. FSH at month 3 was associated with POI, but only modestly with spontaneous pregnancy (OR:0.96; 95 %CI: 0.93–1.00); other factors were not predictive of pregnancy.</div></div><div><h3>Conclusion</h3><div>Hormonal factors are associated with pregnancy in BC patients pausing adjuvant ET to conceive, and their assessment may help to optimize fertility counseling.</div></div><div><h3>Trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> number NCT02308085.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104547"},"PeriodicalIF":7.9,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis","authors":"Michele Bottosso ,&nbsp;Christian Zurlo ,&nbsp;Federica Miglietta ,&nbsp;Anna Chiara Cattelan ,&nbsp;Daniela Iannaccone ,&nbsp;Maria Vittoria Dieci ,&nbsp;Gaia Griguolo ,&nbsp;Fabio Girardi ,&nbsp;Valentina Guarneri","doi":"10.1016/j.breast.2025.104544","DOIUrl":"10.1016/j.breast.2025.104544","url":null,"abstract":"<div><h3>Background</h3><div>Almost 60 % of breast cancers (BCs) diagnosed in germline BRCA1/2 mutation (gBRCAm) carriers are HR+/HER2-. Sparse data suggest limited CDK4/6 inhibitors benefit among gBRCAm carriers. However, prespecified subgroup analyses from pivotal trials are lacking, and current data quality is poor given the small patient populations.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of studies evaluating CDK4/6 inhibitors outcomes in patients with HR+/HER2-metastatic BC according to gBRCA status. Progression free survival (PFS) and overall survival (OS) were compared between gBRCAm patients and those with wild type (wt) or unknown (wt/unk) gBRCA status.</div></div><div><h3>Results</h3><div>Of 1339 potentially eligible records, 14 studies were included, covering a population of 618 gBRCAm patients. Studies were mostly retrospective, with moderate-to-high risk of bias according to ROBINS-E algorithm. Three studies included only gBRCA tested patients; all others also allowed gBRCA untested patients.</div><div>Meta-analysis of studies with available data for gBRCAm vs. gBRCAwt patients resulted in an HR for PFS of 1.68 (95 %CI 1.37–2.05) and an HR for OS of 1.73 (95 %CI 1.12–2.67). Inclusion of patients with unknown gBRCA status led to similar results (gBRCAm vs. gBRCAwt/unk), with an HR for PFS of 2.02 (95 %CI 1.59–2.57) and for OS of 1.46 (95 %CI 1.08–2.00).</div></div><div><h3>Conclusions</h3><div>Emerging data suggest that gBRCAm patients with advanced HR+/HER2- BC may experience shorter PFS and OS with CDK4/6 inhibitor compared to gBRCAwt. Given the low level of evidence and the high risk of bias in available studies, further research is needed to understand molecular mechanisms and identify the optimal treatment sequence.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104544"},"PeriodicalIF":7.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Development and evaluation of a decision aid for women eligible for organized breast cancer screening according to international standards: A multi-method study” [Breast 73 (2024) 103613]","authors":"Sandrine Hild ,&nbsp;Delphine Teigné ,&nbsp;Damien Fairier ,&nbsp;Yannick Ruelle ,&nbsp;Isabelle Aubin-Auger ,&nbsp;Stéphanie Sidorkiewicz ,&nbsp;Marie Citrini ,&nbsp;Xavier Gocko ,&nbsp;Catherine Cerisey ,&nbsp;Emilie Ferrat ,&nbsp;Cédric Rat","doi":"10.1016/j.breast.2025.104529","DOIUrl":"10.1016/j.breast.2025.104529","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104529"},"PeriodicalIF":5.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer","authors":"Julie Leblanc ,&nbsp;Alexandre de Nonneville ,&nbsp;Camille Nicolas ,&nbsp;Anthony Gonçalves ,&nbsp;Véronique Favrel ,&nbsp;Marguerite Tyran ,&nbsp;Morgan Guenole ,&nbsp;Leonel Varela ,&nbsp;Laurence Gonzague ,&nbsp;Agnès Tallet ,&nbsp;Claire Petit","doi":"10.1016/j.breast.2025.104546","DOIUrl":"10.1016/j.breast.2025.104546","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"83 ","pages":"Article 104546"},"PeriodicalIF":7.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}